Eloralintide vs Retatrutide
Eloralintide (LY3841136) and Retatrutide (LY3437943) are both investigational compounds, but they represent completely different bets on the next generation of obesity pharmacology. Retatrutide adds a third receptor (glucagon) to the incretin backbone; Eloralintide brings in the entirely separate amylin axis. This page compares them as research compounds.
| Eloralintide | Retatrutide | |
|---|---|---|
| Development code | LY3841136 | LY3437943 |
| Receptor targets | Amylin receptors (selective) | GLP-1, GIP, glucagon (triple) |
| Mechanism family | Amylin analogue | Incretin + glucagon agonist |
| Development stage | ENLIGHTEN Phase 3 | TRIUMPH Phase 3 |
| Peak Phase 2 body-weight reduction | 9.5% to 20.1% at 48 weeks | 24.2% at 12mg by 48 weeks |
| Phase 3 result | Not yet reported | TRIUMPH-1: 17.6% to 25.0% at 80 weeks (placebo 3.9%) |
| Typical combination partner | Tirzepatide (dual incretin) | Standalone triple agonist |
| Peptx availability | Factory Direct kits; UK single vials on waitlist | UK single vials and Factory Direct kits |
- Development code
- LY3841136LY3437943
- Receptor targets
- Amylin receptors (selective)GLP-1, GIP, glucagon (triple)
- Mechanism family
- Amylin analogueIncretin + glucagon agonist
- Development stage
- ENLIGHTEN Phase 3TRIUMPH Phase 3
- Peak Phase 2 body-weight reduction
- 9.5% to 20.1% at 48 weeks24.2% at 12mg by 48 weeks
- Phase 3 result
- Not yet reportedTRIUMPH-1: 17.6% to 25.0% at 80 weeks (placebo 3.9%)
- Typical combination partner
- Tirzepatide (dual incretin)Standalone triple agonist
- Peptx availability
- Factory Direct kits; UK single vials on waitlistUK single vials and Factory Direct kits
Two very different approaches to next-gen obesity pharmacology
Retatrutide's approach is receptor multi-agonism within a single molecule: keep the dual GLP-1/GIP incretin activity of Tirzepatide, then add a third arm at the glucagon receptor to drive additional adipose-mass change through hepatic pathways and thermogenesis. In Phase 2 it reached 24.2% at 48 weeks, and its Phase 3 TRIUMPH-1 trial reported up to 25.0% at 80 weeks.
Eloralintide's approach is combination rather than multi-agonism: keep the incretin backbone as a separate molecule (Tirzepatide), and pair it with a selective amylin agonist that operates on an entirely different receptor family. The bet is that non-overlapping receptor pharmacology gives you flexibility, cleaner dose-titration, and potentially better tolerability than a single-molecule triple agonist.
Which one is winning?
It is too early to tell. Retatrutide is further along: its Phase 3 TRIUMPH-1 trial, published in September 2026, reported up to 25.0% at 80 weeks. Eloralintide reached 9.5% to 20.1% on its own in Phase 2, and combined with Tirzepatide it reached 23.3% in a 2026 Phase 2b in adults with type 2 diabetes. Eloralintide's Phase 3 has not reported, and no trial has compared the two directly.
For research labs the two compounds are complementary. Retatrutide is the reference for studying receptor multi-agonism within a single molecule. Eloralintide is the reference for studying combination pharmacology across two mechanistically independent axes.
Retatrutide and Eloralintide in one vial
Retalora is a research blend of Retatrutide 10mg and Eloralintide 2.5mg in a single lyophilised vial, now in UK Express. See Retalora.
Between them the two compounds act on four receptors: GLP-1, GIP, glucagon and amylin. Read what the research says about the two together and how this differs from a single-molecule quad agonist.
Bottom line for research labs
For research labs modelling next-generation obesity pharmacology, both compounds are relevant but they answer different questions. Retatrutide is the reference for triple-agonist single-molecule pharmacology and has the deepest monotherapy dataset. Eloralintide is the reference for selective amylin pharmacology and combination-with-incretin research. Serious mechanism-of-action work often uses both.